Liposomes for tumor-targeted therapy

Akira Ito, Hiroyuki Honda, Takeshi Kobayashi

Research output: Contribution to journalArticle

Abstract

Liposomes are the models of membranes. Liposomalization of various drugs has revealed the enhancement of their efficacy : Since liposomes can reduce the side effect of the drugs by the sitespecific delivery, intracellular targeting, and controlled release of drugs, many functional liposomes have been developed including cationic liposomes and antibody-conjugating im munoliposomes. In this article, the preparation and characterization of functional liposomes are discussed. We have developed intracellular hyperthermia using magnetic nanoparticles (magnet ites) by the feature that magnetites can generate heat under high frequency alternative magnetic field. In addition, magnetites affect the magnetic gradient in a magnetic field and those can be used as a contrast enhancement reagent for MRI. Therefore, if magnetite can be accumulated only in tumor tissue, they can afford cancer diagnosis and tumor-specific hyperthermia. To deliver the magnetites toward tumors, two kinds of functional liposomes have been developed, which were “gmagnetite cationic liposomes(IVICLs)” and “Fab '-conjugating magnetoliposomes (FMLs)”. MCLs were designed for the intratumor injection and showed the high affinity to the tumor cells. On the other hands, FMLs were designed for “missile liposomes” which can accumu late in the tumor by antigens-antibody reaction even in the case of intravascular injection. Here, we review these functional liposomes and discussed how to achieve the ultimate goal for umor targeting.

Original languageEnglish
Pages (from-to)347-354
Number of pages8
JournalDrug Delivery System
Volume17
Issue number4
DOIs
Publication statusPublished - Jan 1 2002
Externally publishedYes

Fingerprint

Liposomes
Ferrosoferric Oxide
Neoplasms
Therapeutics
Magnetic Fields
Magnetite Nanoparticles
Fever
Antigen-Antibody Reactions
Neoplasm Antibodies
Injections
Neoplasm Antigens
Drug-Related Side Effects and Adverse Reactions
Hot Temperature
Membranes
Antibodies
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Ito, A., Honda, H., & Kobayashi, T. (2002). Liposomes for tumor-targeted therapy. Drug Delivery System, 17(4), 347-354. https://doi.org/10.2745/dds.17.347

Liposomes for tumor-targeted therapy. / Ito, Akira; Honda, Hiroyuki; Kobayashi, Takeshi.

In: Drug Delivery System, Vol. 17, No. 4, 01.01.2002, p. 347-354.

Research output: Contribution to journalArticle

Ito, A, Honda, H & Kobayashi, T 2002, 'Liposomes for tumor-targeted therapy', Drug Delivery System, vol. 17, no. 4, pp. 347-354. https://doi.org/10.2745/dds.17.347
Ito, Akira ; Honda, Hiroyuki ; Kobayashi, Takeshi. / Liposomes for tumor-targeted therapy. In: Drug Delivery System. 2002 ; Vol. 17, No. 4. pp. 347-354.
@article{5d6f5ffde5104587b5b3a8ecc7c1dfa0,
title = "Liposomes for tumor-targeted therapy",
abstract = "Liposomes are the models of membranes. Liposomalization of various drugs has revealed the enhancement of their efficacy : Since liposomes can reduce the side effect of the drugs by the sitespecific delivery, intracellular targeting, and controlled release of drugs, many functional liposomes have been developed including cationic liposomes and antibody-conjugating im munoliposomes. In this article, the preparation and characterization of functional liposomes are discussed. We have developed intracellular hyperthermia using magnetic nanoparticles (magnet ites) by the feature that magnetites can generate heat under high frequency alternative magnetic field. In addition, magnetites affect the magnetic gradient in a magnetic field and those can be used as a contrast enhancement reagent for MRI. Therefore, if magnetite can be accumulated only in tumor tissue, they can afford cancer diagnosis and tumor-specific hyperthermia. To deliver the magnetites toward tumors, two kinds of functional liposomes have been developed, which were “gmagnetite cationic liposomes(IVICLs)” and “Fab '-conjugating magnetoliposomes (FMLs)”. MCLs were designed for the intratumor injection and showed the high affinity to the tumor cells. On the other hands, FMLs were designed for “missile liposomes” which can accumu late in the tumor by antigens-antibody reaction even in the case of intravascular injection. Here, we review these functional liposomes and discussed how to achieve the ultimate goal for umor targeting.",
author = "Akira Ito and Hiroyuki Honda and Takeshi Kobayashi",
year = "2002",
month = "1",
day = "1",
doi = "10.2745/dds.17.347",
language = "English",
volume = "17",
pages = "347--354",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "4",

}

TY - JOUR

T1 - Liposomes for tumor-targeted therapy

AU - Ito, Akira

AU - Honda, Hiroyuki

AU - Kobayashi, Takeshi

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Liposomes are the models of membranes. Liposomalization of various drugs has revealed the enhancement of their efficacy : Since liposomes can reduce the side effect of the drugs by the sitespecific delivery, intracellular targeting, and controlled release of drugs, many functional liposomes have been developed including cationic liposomes and antibody-conjugating im munoliposomes. In this article, the preparation and characterization of functional liposomes are discussed. We have developed intracellular hyperthermia using magnetic nanoparticles (magnet ites) by the feature that magnetites can generate heat under high frequency alternative magnetic field. In addition, magnetites affect the magnetic gradient in a magnetic field and those can be used as a contrast enhancement reagent for MRI. Therefore, if magnetite can be accumulated only in tumor tissue, they can afford cancer diagnosis and tumor-specific hyperthermia. To deliver the magnetites toward tumors, two kinds of functional liposomes have been developed, which were “gmagnetite cationic liposomes(IVICLs)” and “Fab '-conjugating magnetoliposomes (FMLs)”. MCLs were designed for the intratumor injection and showed the high affinity to the tumor cells. On the other hands, FMLs were designed for “missile liposomes” which can accumu late in the tumor by antigens-antibody reaction even in the case of intravascular injection. Here, we review these functional liposomes and discussed how to achieve the ultimate goal for umor targeting.

AB - Liposomes are the models of membranes. Liposomalization of various drugs has revealed the enhancement of their efficacy : Since liposomes can reduce the side effect of the drugs by the sitespecific delivery, intracellular targeting, and controlled release of drugs, many functional liposomes have been developed including cationic liposomes and antibody-conjugating im munoliposomes. In this article, the preparation and characterization of functional liposomes are discussed. We have developed intracellular hyperthermia using magnetic nanoparticles (magnet ites) by the feature that magnetites can generate heat under high frequency alternative magnetic field. In addition, magnetites affect the magnetic gradient in a magnetic field and those can be used as a contrast enhancement reagent for MRI. Therefore, if magnetite can be accumulated only in tumor tissue, they can afford cancer diagnosis and tumor-specific hyperthermia. To deliver the magnetites toward tumors, two kinds of functional liposomes have been developed, which were “gmagnetite cationic liposomes(IVICLs)” and “Fab '-conjugating magnetoliposomes (FMLs)”. MCLs were designed for the intratumor injection and showed the high affinity to the tumor cells. On the other hands, FMLs were designed for “missile liposomes” which can accumu late in the tumor by antigens-antibody reaction even in the case of intravascular injection. Here, we review these functional liposomes and discussed how to achieve the ultimate goal for umor targeting.

UR - http://www.scopus.com/inward/record.url?scp=85024446407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024446407&partnerID=8YFLogxK

U2 - 10.2745/dds.17.347

DO - 10.2745/dds.17.347

M3 - Article

AN - SCOPUS:85024446407

VL - 17

SP - 347

EP - 354

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 4

ER -